Skip to content

Net Income at other companies

Eli Lilly logo
Eli LillyLLY
$7.4B+168%
Pfizer logo
PfizerPFE
$2.69B-9.4%
Rogers Corporation logo
Rogers CorporationROG
$4.5M+421%
Amgen logo
AmgenAMGN
$1.82B+5.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$727.2M-10.1%
Incyte logo
IncyteINCY
$303.33M+91.7%

Other financials

Income statement

See full
Revenue$15.0K-97.8%
Operating income-$84.4M-34.6%
EPS (diluted)-$1.18-45.7%

Balance sheet

See full
Cash & equivalents$35.7M+109%
Total debt$1.9M-44.3%
Total equity$456.2M-35.1%
Total assets$511.3M-30.9%

Cash flow

See full
Operating cash flow-$65.6M-20.6%
CapEx$1.6M+518%
Free cash flow-$67.2M-23.0%

Valuation

See full
Market cap$2.59B+75.2%
Enterprise value$2.55B+74.4%
P/S2,989.2×+2,794×

Profitability

See full
Operating margin-35,688.5%-39,114pp
Net margin-32,753.6%-35,519pp
FCF margin-26,125.8%-28,907pp

Returns & leverage

See full
Return on equity-48.9%-498pp
Debt / equity0.0×
Current ratio8.9×-12.7×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celldex Therapeutics's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celldex Therapeutics's net income?
Celldex Therapeutics (CLDX) reported net income of -$78.69M in Q1 2026.
How has Celldex Therapeutics's net income changed year-over-year?
Celldex Therapeutics's net income decreased by 46.3% year-over-year, from -$53.8M to -$78.69M.
What is the long-term trend for Celldex Therapeutics's net income?
Over 4 years (2021 to 2025), Celldex Therapeutics's net income has grown at a 38.4% compound annual growth rate (CAGR), from -$70.51M to -$258.76M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.